

1 CLAIMS

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

1. A marker for bladder cancer, prostate cancer or urinary infection, the marker consisting a 37KDa fragment of EGFR.

2. A method for the diagnosis of first presentation or recurrence of bladder cancer, the method consisting of the detection of a 37KDa fragment of EGFR in a urine sample.

3. A method as claimed in claim 2 wherein the presence of the 37KDa EGFR fragment is detected using an antibody.

4. A method as claimed in claim 2 or claim 3 wherein the presence of 37KDa EGFR fragment is detected using antibody Ab4 EGFR available from Oncogene Science, Inc.

5. The use of antibody Ab4 EGFR in a test to detect the presence of 37KDa EGFR fragment in urine as a diagnostic test for bladder cancer.

6. A method for the diagnosis of prostate cancer, the method comprising the detection of a 37KDa fragment of EGFR in a urine sample.

7. A method as claimed in claim 6 wherein the presence of the 37KDa EGFR fragment is detected using an antibody.

8. A method as claimed in claim 6 or claim 7 wherein the presence of 37KDa EGFR fragment is detected using antibody Ab4 EGFR available from Oncogene Science, Inc.

16

- 3Vh
A2
- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
9. The use of antibody Ab4 EGFR in a test to detect the presence of 37KDa EGFR fragment in urine as a diagnostic test for prostate cancer.
10. A method for the diagnosis of bladder cancer, and/or prostate cancer and/or urinary infection, the method comprising a test for the presence of a 37KDa fragment of EGFR in a urine sample.
11. A method as claimed in any of claims 2 to 4 and 7 to 10 in the form of a dip-stick test.
12. The use of antibodies to the 37KDa fragment of EGFR in the diagnosis of urinary infection, bladder cancer and prostate cancer.

009903235-00001

19

/s/ [illegible]

AMENDED SHEET